Consonance-HFW Acquisition Corp.

We are a newly established blank check company targeting companies in the biotechnology sector, with our management team having extensive experience in these areas. We will focus on identifying target businesses in developed countries, including but not limited to the United States and European nations. Our operational professionals and board members bring together a wide range of therapeutic area expertise, including hematology, oncology, autoimmune diseases, inflammatory conditions, and rare diseases; extensive regulatory filings in the U.S. and EU, including Investigational New Drug (IND) applications, Breakthrough Therapy Designation applications, New Drug Applications (NDA), and Marketing Authorization Applications (MAA); rich operational experience covering various therapeutic modalities (including small molecules, biologics, and cell therapies); and leadership in strategic priority areas for external opportunities, achieving diversification and growth through business development, product lifecycle management, public and private financing, mergers and acquisitions, scientific, translational, clinical, and regulatory strategies, as well as manufacturing.